The experience of using botulinum toxin type A in combination with hemagglutinin in the treatment of erythematotelangiectatic rosacea
Vestnik dermatologii i venerologii · 2026-07-14 · 102 (4) · 49-57
DOI: 10.25208/vdv17004 ↗Abstract
BACKGROUND: Rosacea is characterized by frequent relapses, resistance to conventional pharmacotherapy, and short remission periods. These challenges underscore the need for alternative therapeutic strategies, including the use of a domestically produced botulinum toxin type A. AIM: To evaluate the efficacy and safety of botulinum toxin type A in combination with hemagglutinin for the treatment of erythematotelangiectatic rosacea of varying severity. METHODS: The study included 35 patients diagnosed with L71.8 (erythematotelangiectatic rosacea) according to ICD-10. Disease severity was assessed using the Adaskevich V.P. Scale or the Rosacea Diagnostic Assessment Scale based on the severity of subjective symptoms. Clinical efficacy was determined based on the time profile of subjective complaints and objective symptoms. Statistical analysis was performed using RStudio and the R programming language. RESULTS: Following mesotherapy with botulinum toxin type A in combination with hemagglutinin, the most frequently observed outcome regardless of severity was partial remission (61–71 %), whereas disease stabilization occurred less often (14–36 %). Complete remission was observed only in isolated cases, and there were no reports of disease progression or relapses. No adverse events were reported. CONCLUSION: Botulinum toxin type A in combination with hemagglutinin demonstrated a favorable efficacy and safety profile in patients with mild-to-moderate erythematotelangiectatic rosacea.
EUVIMED